A detailed history of Edgestream Partners, L.P. transactions in Tg Therapeutics, Inc. stock. As of the latest transaction made, Edgestream Partners, L.P. holds 53,738 shares of TGTX stock, worth $1.91 Million. This represents 0.07% of its overall portfolio holdings.

Number of Shares
53,738
Holding current value
$1.91 Million
% of portfolio
0.07%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Feb 06, 2025

BUY
$21.31 - $35.09 $1.15 Million - $1.89 Million
53,738 New
53,738 $1.62 Million
Q3 2023

Nov 14, 2023

BUY
$8.36 - $26.5 $526,663 - $1.67 Million
62,998 Added 231.36%
90,227 $754,000
Q2 2023

Aug 10, 2023

BUY
$15.48 - $35.0 $421,504 - $953,015
27,229 New
27,229 $676,000

Others Institutions Holding TGTX

About TG THERAPEUTICS, INC.


  • Ticker TGTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 145,274,000
  • Market Cap $5.17B
  • Description
  • TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hod...
More about TGTX
Track This Portfolio

Track Edgestream Partners, L.P. Portfolio

Follow Edgestream Partners, L.P. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Edgestream Partners, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Edgestream Partners, L.P. with notifications on news.